Pharma & Biotech

AstraZeneca
AZN sees potential for their Airsupra product to revolutionize asthma treatment in the U.S., given the large number of inhaler prescriptions annually.
Merck & Co
Merk has acquired Eyebiotech Limited (EyeBio), making it a wholly-owned subsidiary.
Sanofi
SNY announces three new regulatory approvals: expanded uses for Dupixent in the US and Japan, and approval for Beyfortus in Japan.
Merck & Co
At the EUROGIN Congress, MRK announced plans for a new clinical program to develop a multi-valent HPV vaccine that aims to protect against a wider range of HPV types, particularly those affecting African and Asian populations.
Boston Scientific
Global expansion is a strategic focus for the company as it seeks to enhance net sales and market share.
Thermo Fisher Scientific
The company is the global leader in cell culture media and single-use technology for producing biotech pharmaceuticals. It also has a rapidly growing purifying business. TMO has consistently outperformed the market for a long time, contributing significantly to growth.
biogen
LEQEMBI’s global sales increased significantly in the first quarter, hitting over $19 million, nearly tripling Q4FY23 results.
Abbott Laboratories
ABT is developing a new Alinity system to enter a market that it presently does not offer. In addition, the company has a good opportunity to reach emerging markets with biosimilars while remaining capital-efficient.
Novartis
Novartis has made significant progress in its pipeline development and regulatory milestones, demonstrating its commitment to innovation and pipeline progression.
Twist Bioscience
Twist Bioscience’s synthetic genes are a crucial part of its revenue stream, accounting for approximately 30% of total revenue.
Agilent Technologies
Agilent Technologies has introduced the ProteoAnalyzer system, an innovative automated parallel capillary electrophoresis solution for protein analysis, which strengthens the company’s competitive positioning in the analytical instruments space.
Takeda Pharmaceutical
Takeda Pharmaceutical’s increasing research and development (R&D) expenses potentially impacting its profitability and the importance of a robust product pipeline is supported by the provided sources.